Aptevo Therapeutics Approves 1-for-20 Reverse Stock Split

An update from Aptevo Therapeutics ( (APVO) ) is now available.

On May 14, 2025, Aptevo Therapeutics Inc. held a Special Meeting of Stockholders where a reverse stock split was approved, allowing the Board to choose a split ratio between 1-for-6 and 1-for-20. On May 21, 2025, the Board decided on a 1-for-20 reverse stock split, which was implemented on May 23, 2025. This adjustment consolidates every 20 shares into one, affecting stock options, restricted stock units, and warrants proportionately. Trading on a split-adjusted basis will begin on May 27, 2025, on The Nasdaq Capital Market.

The most recent analyst rating on (APVO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.

Spark’s Take on APVO Stock

According to Spark, TipRanks’ AI Analyst, APVO is a Underperform.

Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.

To see Spark’s full report on APVO stock, click here.

More about Aptevo Therapeutics

Average Trading Volume: 5,007,388

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.43M

For detailed information about APVO stock, go to TipRanks’ Stock Analysis page.